A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Brolucizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Pharmacokinetics
  • Sponsors Alcon
  • Most Recent Events

    • 27 Sep 2016 Status changed from recruiting to completed.
    • 19 May 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
    • 19 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top